{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:31:24Z","timestamp":1776353484355,"version":"3.51.2"},"reference-count":50,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Luoda Biosciences, Inc.","award":["LD2022-109"],"award-info":[{"award-number":["LD2022-109"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274369"],"award-info":[{"award-number":["82274369"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32473079"],"award-info":[{"award-number":["32473079"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Life"],"abstract":"<jats:p>Sepsis is a life-threatening condition driven by a dysregulated host response to infection, with high mortality and few treatment options. Decades of failed drug development underscore the urgent need for therapies with novel mechanisms of action. Vimentin, an intermediate filament protein, acts as a network hub that senses and integrates cellular signals. Its involvement in key sepsis pathologies, including infection, hyperinflammation, immunosuppression, coagulopathy and metabolic dysregulation, positions it as a potential therapeutic target. This study evaluated the efficacy of ALD-R491, a novel small-molecule vimentin modulator, in a murine model of polymicrobial sepsis induced by cecal ligation and puncture (CLP). Mice received ALD-R491 prophylactically or therapeutically, alone or with ceftriaxone. The treatment significantly reduced serum levels of key biomarkers of sepsis, including C-reactive protein (CRP), lactate (Lac), tumor necrosis factor-alpha (TNF-\u03b1) and interleukin-6 (IL-6), and dose-dependently improved the survival of septic mice. Organ-specific analysis confirmed the effects of ALD-R491 in mitigating hyperinflammation and multi-organ injury. The treatment reduced pulmonary edema and inflammation; preserved liver tissue architecture and improved hepatic function with lowered alanine aminotransferase\/aspartate aminotransferase (ALT\/AST); decreased kidney tubular damage; and improved renal function with lowered creatinine\/blood urea nitrogen (BUN). These preclinical findings indicate that the vimentin-targeting agent ALD-R491 represents a promising therapeutic candidate for sepsis and merits further clinical investigation.<\/jats:p>","DOI":"10.3390\/life15101563","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T08:10:51Z","timestamp":1759738251000},"page":"1563","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oral Treatment with the Vimentin-Targeting Compound ALD-R491 Mitigates Hyperinflammation, Multi-Organ Injury, and Mortality in CLP-Induced Septic Mice"],"prefix":"10.3390","volume":"15","author":[{"given":"Jianping","family":"Wu","sequence":"first","affiliation":[{"name":"Laboratory Animal Center, Nanjing University of Chinese Medicine, Nanjing 210023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaishuai","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuai","family":"Yu","sequence":"additional","affiliation":[{"name":"School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijing","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueting","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3982-3170","authenticated-orcid":false,"given":"Deebie","family":"Symmes","sequence":"additional","affiliation":[{"name":"Aluda Pharmaceuticals, Inc., Union City, CA 94587, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Mo","sequence":"additional","affiliation":[{"name":"Aluda Pharmaceuticals, Inc., Union City, CA 94587, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0641-2132","authenticated-orcid":false,"given":"Ruihuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Aluda Pharmaceuticals, Inc., Union City, CA 94587, USA"},{"name":"Luoda Biosciences, Inc., Chuzhou 239234, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (2025, March 28). What Is Sepsis?, Available online: https:\/\/www.cdc.gov\/sepsis\/about\/index.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/CCM.0000000000004226","article-title":"Sepsis Among Medicare Beneficiaries: 2. The Trajectories of Sepsis, 2012\u20132018","volume":"48","author":"Buchman","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: Analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"ref_5","unstructured":"World Health Organization (2020). Global Report on the Epidemiology and Burden of Sepsis: Current Evidence, Identifying Gaps and Future Directions, World Health Organization."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e10128","DOI":"10.15252\/emmm.201810128","article-title":"Sepsis therapies: Learning from 30 years of failure of translational research to propose new leads","volume":"12","author":"Cavaillon","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Jarczak, D., Kluge, S., and Nierhaus, A. (2021). Sepsis\u2014Pathophysiology and Therapeutic Concepts. Front. Med., 8.","DOI":"10.3389\/fmed.2021.628302"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0092-8674(94)90553-3","article-title":"Mice lacking vimentin develop and reproduce without an obvious phenotype","volume":"79","author":"Portier","year":"1994","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1101\/gad.349358.122","article-title":"Roles of vimentin in health and disease","volume":"36","author":"Ridge","year":"2022","journal-title":"Genes Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"jcs260509","DOI":"10.1242\/jcs.260509","article-title":"The diverse actions of cytoskeletal vimentin in bacterial infection and host defense","volume":"136","author":"Miao","year":"2023","journal-title":"J. Cell Sci."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mak, T.N., and Br\u00fcggemann, H. (2016). Vimentin in Bacterial Infections. Cells, 5.","DOI":"10.3390\/cells5020018"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ramos, I., Stamatakis, K., Oeste, C.L., and P\u00e9rez-Sala, D. (2020). Vimentin as a Multifaceted Player and Potential Therapeutic Target in Viral Infections. Int. J. Mol. Sci., 21.","DOI":"10.20944\/preprints202005.0041.v1"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mor-Vaknin, N., Legendre, M., Yu, Y., Serezani, C.H., Garg, S.K., Jatzek, A., Swanson, M.D., Gonzalez-Hernandez, M.J., Teitz-Tennenbaum, S., and Punturieri, A. (2013). Murine colitis is mediated by vimentin. Sci. Rep., 3.","DOI":"10.1038\/srep01045"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1038\/ncomms7574","article-title":"Vimentin regulates activation of the NLRP3 inflammasome","volume":"6","author":"Rogel","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1172\/JCI95713","article-title":"The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease","volume":"128","author":"Muller","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1038\/s41467-022-30063-7","article-title":"Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy","volume":"13","author":"Huijbers","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2013-10-530428","article-title":"Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress","volume":"123","author":"Da","year":"2014","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.thromres.2022.11.028","article-title":"A novel interaction between extracellular vimentin and fibrinogen in fibrin formation","volume":"221","author":"Cebula","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mohanasundaram, P., Coelho-Rato, L.S., Modi, M.K., Urbanska, M., Lautenschl\u00e4ger, F., Cheng, F., and Eriksson, J.E. (2022). Cytoskeletal vimentin regulates cell size and autophagy through mTORC1 signaling. PLoS Biol., 20.","DOI":"10.1371\/journal.pbio.3001737"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Su, L., Pan, P., Yan, P., Long, Y., Zhou, X., Wang, X., Zhou, R., Wen, B., Xie, L., and Liu, D. (2019). Role of vimentin in modulating immune cell apoptosis and inflammatory responses in sepsis. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-42287-7"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"113188","DOI":"10.1016\/j.ejmech.2021.113188","article-title":"SARs of a novel series of s-triazine compounds targeting vimentin to induce methuotic phenotype","volume":"214","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kim, H.R., Warrington, S.J., L\u00f3pez-Guajardo, A., Al Hennawi, K., Cook, S.L., Griffith, Z.D.J., Symmes, D., Zhang, T., Qu, Z., and Xu, Y. (2022). ALD-R491 regulates vimentin filament stability and solubility, cell contractile force, cell migration speed and directionality. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.926283"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Li, Z., Wu, J., Zhou, J., Yuan, B., Chen, J., Wu, W., Mo, L., Qu, Z., Zhou, F., and Dong, Y. (2021). A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases. mBio, 12.","DOI":"10.1128\/mBio.02542-21"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E4320","DOI":"10.1073\/pnas.1519197113","article-title":"Vimentin coordinates fibroblast proliferation and keratinocyte differentiation in wound healing via TGF-\u03b2-Slug signaling","volume":"113","author":"Cheng","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/s41556-025-01713-x","article-title":"Vimentin intermediate filaments as structural and mechanical coordinators of mesenchymal cells","volume":"27","author":"Guo","year":"2025","journal-title":"Nat. Cell Biol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Rosier, M., Krstulovi\u0107, A., Kim, H.R., Kaur, N., Enakireru, E.M., Symmes, D., Dobra, K., Chen, R., Evans, C.A., and Gad, A.K.B. (2024). The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells. Cancers, 17.","DOI":"10.20944\/preprints202412.0008.v1"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wu, J., Xie, Q., Liu, Y., Gao, Y., Qu, Z., Mo, L., Xu, Y., Chen, R., and Shi, L. (2021). A Small Vimentin-Binding Molecule Blocks Cancer Exosome Release and Reduces Cancer Cell Mobility. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.627394"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wu, J., Wu, X., Cheng, C., Liu, L., Xu, L., Xu, Z., Wang, S., Symmes, D., Mo, L., and Chen, R. (2023). Therapeutic targeting of vimentin by ALD-R491 impacts multiple pathogenic processes to attenuate acute and chronic colitis in mice. Biomed. Pharmacother., 168.","DOI":"10.1016\/j.biopha.2023.115648"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-1-4939-9167-9_22","article-title":"Sepsis Induced by Cecal Ligation and Puncture","volume":"1960","author":"Gong","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4049\/immunohorizons.2100027","article-title":"Prolonged Reactive Oxygen Species Production following Septic Insult","volume":"5","author":"Jensen","year":"2021","journal-title":"Immunohorizons"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nprot.2008.214","article-title":"Immunodesign of experimental sepsis by cecal ligation and puncture","volume":"4","author":"Rittirsch","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"771","DOI":"10.7326\/0003-4819-119-8-199310150-00001","article-title":"Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome","volume":"119","author":"Casey","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM198806093182301","article-title":"Detection of circulating tumor necrosis factor after endotoxin administration","volume":"318","author":"Michie","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0891-5520(05)70083-0","article-title":"Cytokines and Anticytokines in the Pathogenesis of Sepsis","volume":"13","year":"1999","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJM199606273342603","article-title":"Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein","volume":"334","author":"Fisher","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gao, Q., Yin, X., Tan, B., Wang, J., Chen, J., Zhao, B., Yang, Q., and Li, Z. (2022). Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07896-0"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00003246-199707000-00010","article-title":"Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial","volume":"25","author":"Opal","year":"1997","journal-title":"Crit. Care Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41581-018-0005-7","article-title":"Mechanisms and treatment of organ failure in sepsis","volume":"14","author":"Lelubre","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"ofy313","DOI":"10.1093\/ofid\/ofy313","article-title":"Sepsis in Intensive Care Unit Patients: Worldwide Data from the Intensive Care over Nations Audit","volume":"5","author":"Sakr","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.chest.2019.05.030","article-title":"POINT: Should Broad-Spectrum Antibiotics Be Routinely Administered to All Patients with Sepsis as Soon as Possible? Yes","volume":"156","author":"Disselkamp","year":"2019","journal-title":"Chest"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.chest.2019.05.033","article-title":"Rebuttal from Drs Patel and Bergl","volume":"156","author":"Patel","year":"2019","journal-title":"Chest"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"107791","DOI":"10.1016\/j.intimp.2021.107791","article-title":"The roles of macrophage polarization in the host immune response to sepsis","volume":"96","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cmet.2021.02.010","article-title":"Mitochondrial dysfunction defines T cell exhaustion","volume":"33","author":"Mittelbrunn","year":"2021","journal-title":"Cell Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40635-022-00471-6","article-title":"T cell dysregulation in inflammatory diseases in ICU","volume":"10","author":"Luperto","year":"2022","journal-title":"Intensive Care Med. Exp."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jmii.2012.06.012","article-title":"Increased proportion of CD4+CD25+Foxp3+ regulatory T cells during early-stage sepsis in ICU patients","volume":"46","author":"Leng","year":"2013","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00134-008-1337-8","article-title":"Increased circulating regulatory T cells (CD4+CD25+CD127\u2212) contribute to lymphocyte anergy in septic shock patients","volume":"35","author":"Venet","year":"2009","journal-title":"Intensive Care Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/labinvest.2013.69","article-title":"M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4\/IL-10 signaling pathway","volume":"93","author":"Liu","year":"2013","journal-title":"Lab. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1189\/jlb.0405190","article-title":"Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis","volume":"79","author":"Moisan","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"k3284","DOI":"10.1136\/bmj.k3284","article-title":"Corticosteroid therapy for sepsis: A clinical practice guideline","volume":"362","author":"Lamontagne","year":"2018","journal-title":"BMJ"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1242\/jcs.180315","article-title":"Vimentin filaments regulate integrin-ligand interactions by binding to the cytoplasmic tail of integrin \u03b23","volume":"129","author":"Kim","year":"2016","journal-title":"J. Cell Sci."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/10\/1563\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T08:24:59Z","timestamp":1759739099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/10\/1563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["life15101563"],"URL":"https:\/\/doi.org\/10.3390\/life15101563","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]}}}